Tags : (AML)


Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative

Shots: Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML   The companies will utilize ASCO’s CancerLinQ Discovery database of de-identified cancer patient records to improve understanding of responses in patients, AML treatment patterns, disease progression and opportunities for improved QoL The […]Read More


Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia

Shots: On 28 Nov, 2018 Xospata (gilteritinib) received FDA approval as a PO monothx, indicated for r/r FLT3 mutation-positive (FLT3mut+) AML Xospata is accompanied by Xospata Support Solutions offering access and reimbursement support to patients and also provides information regarding patient healthcare coverage options and financial assistance programs Xospata 40 mg (gilteritinib) is a FLT3 […]Read More


Genentech’s Venclexta (venetoclax) Receives FDA’s Accelerated Approval for Patients with

Shots: The accelerated approval is based on M14-358 (P-Ib) & M14-387 study (I/II) results assessing Venclexta (400mg qd) + azacitidine & decitabine & Venclexta (600mg qd) + LDAC (low-dose cytarabine) respectively in patients with 1L AML. or for those ineligible for intensive induction CT aged ≥60 yrs. M14-358 & M14-387 study results: Venclexta + azacitidine […]Read More